



**cTIF™**

## Durable Relief of GERD Symptoms for a Broader Patient Population

**TIF®**  
PROCEDURE  
FOR REFLUX

cTIF (Concomitant Transoral Incisionless Fundoplication) is a TIF® 2.0 procedure preceded directly by laparoscopic hiatal hernia repair (LHHR) providing durable relief of GERD symptoms to a broader patient population with anatomic defects (hernia greater than 2cm) that require correction.

### + Clinical Data Supports Efficacy, Safety and Durability

- Laparoscopic hiatal hernia repair followed by TIF 2.0 in the same surgical session provides a durable<sup>15,16</sup>, efficacious, and safe solution for GERD
- cTIF has shown to be efficacious in normalizing pH scores<sup>3</sup>

### + Lower Side-Effect Profile than Alternative Options

- cTIF produces consistently positive outcomes similar to traditional anti-reflux surgery with lower complication rates absent *de novo* side-effects
- Gas bloat and dysphagia are less likely with cTIF, and patients still have the ability to belch and vomit<sup>10</sup>

### + Restores Anatomy to Its Natural State

- Recreates the dynamics of the Angle of HIS, elongates the intra-abdominal esophagus and restores the distal high pressure zone
- Sparing the fundus and blood supply of the stomach - does not require division of the short gastric vessels
- Rebuilds LES (lower esophageal sphincter) by creating an omega shaped gastroesophageal flap valve (GEFV) (**see Figure 1**) without twisting or torquing the distal esophagus

### + Reproducible & Standardizable Fundoplication

- Building the GEFV around the EsophyX® device (60 French) provides consistent results
- Fundoplication is secured with 20+ fasteners to evenly distribute force across the entire circumference of the wrap
- Valve is created with gastric insufflation, so the stomach is distended, increasing the likelihood of tolerance for air that accumulates with meals<sup>14</sup>

EndoGastric Solutions.



### Improvement in Quality of Life<sup>13</sup>

**73%** Decrease in GERD frequency & severity

**83%** Decrease in regurgitation

**89%** Reduction in PPI use

**94%** Improvement in DeMeester score



Figure 1: Omega-shaped GEFV created with the EsophyX device